|
Cell source | Intervention (s) | Human/animals | Transplanted method | Outcome | Author (year) |
|
MSCs | Cocultured with AML12 hepatocytes | CCl4 liver injury in rats | Implantation in liver | Significant reductions in AST and ALT levels Promoting liver repair and liver tissue regeneration | [8] |
BMSCs | Transplantation | Mice with hepatic failure | | Cholangiocytes can be efficiently differentiated from BMSCs | [25] |
BMSCs | Cultured with HGF | Patients with end-stage liver cell failure | Intrasplenic or intrahepatic injection | Significant improvement in serum ALB The results demonstrated the short-term efficacy of SCs injection in liver cell failure. | [45] |
BMMSCs | Transplantation | CCl4 liver injury in mice | Tail vein injection | Decreased AST and ALT Increased ALB concentration Improved liver regeneration | [40] |
ADSCs | Transplantation | Rats with partial hepatectomy | Portal vein or hepatic parenchyma injection | Significant higher liver regeneration rate Upregulated the expression of hepatic specific markers | [43] |
ADMSC | Transplantation | CCl4 liver injury in mice | Tail vein injection | Prolonged recipient survival Produced ALB and CK-18 | [41] |
UMSC-CM | Transplantation | CCl4 liver injury in rats | Intravenous injection | Improved oxidative status Increased expression of hepatic specific gen and protein level | [38] |
UMSC-CM | Transplantation | CCl4 liver injury in rats | Intravenous injection | Improved oxidative status Increased expression of hepatic specific gen and protein level | [39] |
WJMSCs | Transplantation | CCl4 liver injury in rats | | Decreased liver fibrosis and fibrotic related genes | [14] |
ESCs | Transplantation | Mice with liver injury | Intrasplenic injection | The resulted cells, clonally expanded hepatic progenitor cells repopulated the livers of fah-deficient mice without inducing tumorigenesis | [47] |
ESCs | Transplantation | CCl4 liver injury in mice | Intrasplenic injection | Integrated into the liver and expressed α-1 antitrypsin | [21] |
iPSCs | Transplantation | Mice with ALF | Intrahepatic injection | Prolonged recipient survival | [48] |
iPSCs | Multistage differentiation protocol | Mice with liver cirrhosis | Intraperitoneal injection | Successful repopulation of the liver tissue, also secretion of human-specific liver proteins into mouse blood | [50] |
iPSCs | Transplantation of differentiated cell cultured on recombinant laminin | Inherited liver disease model rats | Splenic injection | Significant bilirubinemia reduction | [46] |
hPSCs | Implantation | Acute liver injury mouse | | These results demonstrated the significant impact of differentiation fate and differentiation efficacy | [37] |
MenSCs | Transplantation | CCL4 liver injury mice | Tail vein injection | Significant liver function improvement Attenuated collagen deposition | [9] |
MenSCs | Transplantation | Pig with ALF | Portal vein injection | Significant reduction of of ALT, AST, TB, and PT levels Prolonged recipient survival | [44] |
FLCs | Transplantation | Mice with ALF | Intrasplenic injection | Expressed ALB, AFP, CK-19, and antitrypsin mRNA | [1] |
HSCs | Transplantation of HSCs | Noninjury sheep model of liver cell deficiency | IP transplantation | Efficiently generated functional hepatocytes secreting ALB | [49] |
HSCs | Transplantation | CCL4 liver injury mice | Tail vein injection | Regenerated of injured liver by differentiating into functional hepatocytes | [42] |
HSLc | Transplantation on type I collagen matrices | Analbuminemic rat | Intraliver injection | Increased in the serum ALB 2.5-fold compared to control group | [16] |
Human liver SC line (HYX1) | Transplantation | Mice with ALF | Intraperitoneal | Decreased level of ALT, AST, TB, and liver injury | [52] |
|